Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Risk of upper GI ulcer bleeds with NSAIDS, aspirin and coxibs

The most recent issue of Gut shows that differences between non-selective NSAIDs and coxibs disappear when given in combination with aspirin.

News image

fiogf49gjkf04

The risks and benefits of coxibs, non-steroidal anti-inflammatory drugs (NSAIDs), and aspirin treatment are under intense debate.

Dr Lanas and colleagues from Spain determined the risk of peptic ulcer upper gastrointestinal (GI) bleeding associated with the use of these drugs both individually, and in combination in clinical practice.

The research team undertook a hospital-based, case-control study in the general community of patients from the National Health System.

The researchers included 2777 consecutive patients with endoscopy-proved major UGIB because of the peptic lesions.

The team matched 5532 controls by age, hospital and month of admission.

Coxibs have a lower risk of upper GI bleeds than non-selective NSAIDs
Gut

The team adjusted relative risk of upper gastrointestinal bleeding determined by conditional logistic regression analysis.

Use of non-aspirin-NSAIDs increased the risk of upper gastrointestinal bleeding.

The researchers found that among non-aspirin-NSAIDs, aceclofenac had the lowest relative risk.

In contrast, the team noted that ketorolac had the highest relative risk among non-aspirin-NSAIDS.

Rofecoxib treatment increased the risk of upper gastrointestinal bleeding.

The researchers observed that celecoxib, paracetamol or concomitant use of a proton pump inhibitor with an NSAID presented no increased risk.

Non-aspirin antiplatelet treatment had a similar risk of upper gastrointestinal bleeding to cardioprotective aspirin at a dose of 100 mg/day or anticoagulants.

The team found an apparent interaction between low-dose aspirin and use of non-aspirin-NSAIDs, coxibs or thienopyridines.

This further increased the risk of upper gastrointestinal bleeding in a similar way.

Dr Lanas' team concludes, “Coxib use presents a lower relative risk of upper gastrointestinal bleeding than non-selective NSAIDs.”

“However, when combined with low-dose aspirin, the differences between non-selective NSAIDs and coxibs tend to disappear.”

“Treatment with either non-aspirin antiplatelet or cardioprotective aspirin has a similar risk of upper gastrointestinal bleeding.”

Gut 2006: 55(12): 1731-8
27 November 2006

Go to top of page Email this page Email this page to a colleague

 20 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 20 April 2018 
Obesity and physical activity in diverticulosis
 20 April 2018 
Worldwide H.pylori prevalence
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Physician perception of IBD trial results
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 06 April 2018 
Microbiome in athletes vs sedentary subjects
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Scoring system identifies cancer risk in Barrett's
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
PPI and risk of stroke
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 
 22 March 2018 
Mechanisms of action in patients with IBS
 21 March 2018 
Panel markers for early detection of colon cancer

 21 March 2018 
Blood test differentiates celiac disease
 21 March 2018 
Patient characteristics and colonoscopy preparation

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us